OR WAIT null SECS
March 15, 2024
The draft guidance document provides support to sponsors with drugs in clinical development that treat the states of sporadic Alzheimer’s disease.
March 14, 2024
Noramco Group will be an integrated North American-based API and supply chain services provider.
In a new manufacturing pact, Chime Biologics will produce DT-7012, Domain Therapeutics' antibody candidate for treating cancer that will soon be entering Phase I studies.
March 13, 2024
The company is investing more than $2 million in its analytical testing services and adding suppository manufacturing capabilities.
March 12, 2024
In an interview, Fabian Gerlinghaus of Cellares outlines a paradigm change in both hardware and software, regulatory expansions, and some positive cost outcomes for the CGT field.
The Cell Shuttle platform will manufacture cell therapies for its first clinical trials by the end of the year.
The European company has seen its business increase by 47% in North America.
March 11, 2024
The Alliance will receive the NSF Regional Innovation Engines Development Award and $1 million in funding.
March 08, 2024
EMA has validated two MAAs submitted by AstraZeneca and Daiichi Sankyo for datopotamab deruxtecan in two types of cancer.
The facility producer’s new innovation hub will offer manufacturing, life sciences, and infrastructure services.